Robot surgery may spare seminoma patients from chemo side effects
NCT ID NCT06144736
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase II trial is testing whether robot-assisted surgery to remove lymph nodes in the abdomen can help predict and prevent cancer recurrence in men with stage II seminoma. About 60 participants will undergo the procedure, with the option of one round of chemotherapy afterward. The goal is to reduce long-term side effects from standard treatments while keeping survival rates high.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Robot-assisted retroperitoneal lymph node dissection (surgery) and optional one cycle of cisplatin, etoposide, and bleomycin (chemotherapy)
- What this could lead to
- If successful, this approach could allow some men with seminoma to avoid long-term side effects of chemotherapy while maintaining high survival rates.
- What could go wrong
- This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. Surgery carries risks like infection or nerve damage, and cancer may still return.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2023
- Expected to finish
-
Aug 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 99 years
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Histologically confirmed pure seminomatous testicular germ cell tumor * Presence of iliac or retroperitoneal lymph node metastasis detected in contrast-enhanced CT or MRI, classified as local or unilaterally regional * Maximum extent of lymph node metastasis (LN-M) singular or multiple, with a maximum size of 5 cm in transverse CT diameter (UICC IIB) * Patients with an elevation in HCG after orchiectomy at the time of staging examination can be included if the directly preoperatively determined HCG does not exceed 5 IU/L. Patients can be included in the following scenarios: * Initial diagnosis of a tumor in UICC stage IIA/IIB * Recurrence of a tumor in clinical stage (CS) I under active surveillance * Recurrence of a CS I tumor after adjuvant therapy with carboplatin mono Exclusion Criteria: * LN-M with a transverse diameter \>5 cm in CT (UICC IIC) * Other metastases than LN-M (UICC III) * The patient received a different chemotherapy than described above * The patient underwent retroperitoneal radiotherapy * The patient is in a reduced general condition or has a life-threatening illness * The patient has a psychiatric illness * Evidence of non-seminomatous germ cell tumor components in the RPLND histology * Complete resection cannot be ensured due to previous surgeries * In the "high risk" group: Contraindications to cisplatin, etoposide, or bleomycin (severe liver insufficiency, severe kidney insufficiency, severe lung insufficiency, hypersensitivity, severe bone marrow depression, profound hearing impairments)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Seminoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University Hospital of Duesseldorf
RECRUITINGDüsseldorf, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can some seminoma patients safely skip heavier treatment?
- High-Dose chemo with stem cell transplant tested against standard therapy for tough germ cell cancers
- New proton beam study aims to cut cancer treatment side effects
- Testicular cancer treatment: which is easier on patients?
- Testicular cancer patients needed for landmark treatment reduction study
- Blood marker may predict cancer return in testicular tumor patients